Recent changes

Track the most recent changes to the wiki on this page.

Recent changes options Show last 50 | 100 | 250 | 500 changes in last 1 | 3 | 7 | 14 | 30 days
Hide registered users | Hide anonymous users | Hide my edits | Hide bots | Hide minor edits
Show new changes starting from 19:31, 30 April 2024

List of abbreviations:

N: This edit created a new page (also see list of new pages)
m: This is a minor edit
b: This edit was performed by a bot
(±123): The page size changed by this number of bytes

30 April 2024

			18:58		User:AED‎‎ 4 changes history +85‎ [Alara E. Dagsali‎ (4×)]
					18:58 (cur \| prev) +20‎ Alara E. Dagsali talk contribs
					18:47 (cur \| prev) +22‎ Alara E. Dagsali talk contribs
					18:28 (cur \| prev) +20‎ Alara E. Dagsali talk contribs
					18:15 (cur \| prev) +23‎ Alara E. Dagsali talk contribs

			N 18:58		Isosulfan Blue‎‎ 2 changes history +5,962‎ [Alara E. Dagsali‎ (2×)]
					18:58 (cur \| prev) +3‎ Alara E. Dagsali talk contribs
			N		18:57 (cur \| prev) +5,959‎ Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage \|authorTag=Alara E.Dagsali \|genericName=Lymphazurin \|aOrAn=a \|indicationType=treatment \|indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape...")

			N 18:47		Ibuprofen Lysine‎‎ 2 changes history +15,666‎ [Alara E. Dagsali‎ (2×)]
					18:47 (cur \| prev) +3‎ Alara E. Dagsali talk contribs
			N		18:46 (cur \| prev) +15,663‎ Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage \|authorTag=Alara E.Dagsali \|OTC=Yes \|genericName=Ibuprofen lysine \|aOrAn=a \|indicationType=treatment \|indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc...")

			N 18:28		Prussian blue‎‎ 2 changes history +14,070‎ [Alara E. Dagsali‎ (2×)]
					18:28 (cur \| prev) +3‎ Alara E. Dagsali talk contribs
			N		18:27 (cur \| prev) +14,067‎ Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage \|authorTag=Alara E.Dagsali \|drugClass=RADIOGARDASE \|indicationType=treatment \|indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination \|adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R...")

			N 18:15		Botulism Antitoxin‎‎ 2 changes history +18,011‎ [Alara E. Dagsali‎ (2×)]
					18:15 (cur \| prev) +3‎ Alara E. Dagsali talk contribs
			N		18:14 (cur \| prev) +18,008‎ Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage \|authorTag=Alara E.Dagsali \|genericName=BAT \|aOrAn=a \|indicationType=treatment \|indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. \|adverseReactions=The most common adverse reactions obse...")

m 15:35

Medication reconciliation‎ diffhist +1‎ Badgettrg talk contribs

29 April 2024

15:26

User:AED‎ diffhist +27‎ Alara E. Dagsali talk contribs

			N 15:25		Trastuzumab emtansine‎‎ 2 changes history +40,575‎ [Alara E. Dagsali‎ (2×)]
					15:25 (cur \| prev) −35‎ Alara E. Dagsali talk contribs
			N		15:23 (cur \| prev) +40,610‎ Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage \|authorTag=AlaraE.Dagsali \|genericName=ado-trastuzumab emtansine \|indicationType=treatment \|indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment...")

28 April 2024

m 06:33

Non-degenerate nucleotides per response element‎ diffhist +207‎ Marshallsumter talk contribs (→‎Tabulation of counts)

27 April 2024

			m 20:10		Non-degenerate nucleotides per response element‎‎ 2 changes history +1,935‎ [Marshallsumter‎ (2×)]
			m		20:10 (cur \| prev) +301‎ Marshallsumter talk contribs (→‎Tabulation of counts)
			m		08:46 (cur \| prev) +1,634‎ Marshallsumter talk contribs (→‎Tabulation of counts)

00:49

Chronic obstructive pulmonary disease history and symptoms‎ diffhist +2,903‎ Kosar Doraghi talk contribs

26 April 2024

			m 20:03		Non-degenerate nucleotides per response element‎‎ 2 changes history +2,239‎ [Marshallsumter‎ (2×)]
			m		20:03 (cur \| prev) +608‎ Marshallsumter talk contribs (→‎Tabulation of counts)
			m		08:34 (cur \| prev) +1,631‎ Marshallsumter talk contribs (→‎Tabulation of counts)

17:32

User creation log User account Jonathan Reyes talk contribs was created by Alberto Castro Molina talk contribs ‎

04:27

Daprodustat‎ diffhist +1,079‎ Alen Antony talk contribs

25 April 2024

22:53

Reni Syndrome‎ diffhist −3‎ Alara E. Dagsali talk contribs

			N 22:52		User:AED‎‎ 3 changes history +3,204‎ [Alara E. Dagsali‎ (3×)]
					22:52 (cur \| prev) −144‎ Alara E. Dagsali talk contribs
					22:51 (cur \| prev) +407‎ Alara E. Dagsali talk contribs
			N		22:39 (cur \| prev) +2,941‎ Alara E. Dagsali talk contribs (Created page with "==Alara Ece Dagsali== '''Alara Ece Dagsali''' <br>'''Contact:''' email: alaraecedagsai99@gmail.com; +905313614710 ==Medical Education== School of Medicine (M.D.): Istanbul Medipol University 2021- 2024 Demiroglu Bilim University 2018-2021 ==Pages authored/Co-authored/Collaborated== ===2023=== ====Authored:==== Reni Syndrome ==Work Experience== Wikidoc - Associate Editor-In-Chief, 2023 - Current Yeditepe University Hospitals Cardiac Electrophysiology Lab, Ista...")

22:48

Adagrasib‎ diffhist +3‎ Alara E. Dagsali talk contribs

22:48

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)‎ diffhist +20‎ Alara E. Dagsali talk contribs

22:45

Norelgestromin‎ diffhist +3‎ Alara E. Dagsali talk contribs

			22:45		Tranexamic‎‎ 6 changes history +1‎ [Alara E. Dagsali‎ (6×)]
					22:45 (cur \| prev) +11‎ Alara E. Dagsali talk contribs
					22:44 (cur \| prev) −11‎ Alara E. Dagsali talk contribs
					22:41 (cur \| prev) +2‎ Alara E. Dagsali talk contribs
					22:41 (cur \| prev) −1‎ Alara E. Dagsali talk contribs
					22:40 (cur \| prev) +14‎ Alara E. Dagsali talk contribs Tag: Manual revert
					22:39 (cur \| prev) −14‎ Alara E. Dagsali talk contribs Tag: Manual revert

22:36

Alara E. Dagsali‎ diffhist +40‎ Alara E. Dagsali talk contribs

			N 21:21		Daprodustat‎‎ 6 changes history +6,894‎ [Alen Antony‎ (6×)]
					21:21 (cur \| prev) +952‎ Alen Antony talk contribs
					20:53 (cur \| prev) +1,266‎ Alen Antony talk contribs
					19:07 (cur \| prev) +2,809‎ Alen Antony talk contribs
					17:23 (cur \| prev) +563‎ Alen Antony talk contribs
					16:47 (cur \| prev) +147‎ Alen Antony talk contribs
			N		15:23 (cur \| prev) +1,157‎ Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage \|authorTag={{AAP}} \|genericName=daprodustat \|aOrAn=a \|drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. \|indicationType=treatment \|indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. \|hasBlackBoxWarning=Yes \|adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...")

			m 17:37		Non-degenerate nucleotides per response element‎‎ 2 changes history +3,020‎ [Marshallsumter‎ (2×)]
			m		17:37 (cur \| prev) +705‎ Marshallsumter talk contribs (→‎Tabulation of counts)
			m		07:56 (cur \| prev) +2,315‎ Marshallsumter talk contribs (→‎Tabulation of counts)

17:03

Chronic hypertension medical therapy‎ diffhist +715‎ Badgettrg talk contribs (→‎Impact of Blood Pressure self-monitoring in Hypertension Control)

			01:50		Bexagliflozin‎‎ 4 changes history +3,949‎ [Alen Antony‎ (4×)]
					01:50 (cur \| prev) +1,145‎ Alen Antony talk contribs
					00:57 (cur \| prev) +669‎ Alen Antony talk contribs
					00:50 (cur \| prev) +1,349‎ Alen Antony talk contribs
					00:17 (cur \| prev) +786‎ Alen Antony talk contribs

24 April 2024

			N 23:35		Bexagliflozin‎‎ 4 changes history +1,938‎ [Alen Antony‎ (4×)]
					23:35 (cur \| prev) +245‎ Alen Antony talk contribs
					23:11 (cur \| prev) +1,453‎ Alen Antony talk contribs
					22:55 (cur \| prev) +164‎ Alen Antony talk contribs
			N		21:06 (cur \| prev) +76‎ Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage \|authorTag={{AAP}} \|genericName=bexagliflozin }}")

23:17

Endocarditis overview‎ diffhist +5,051‎ Kosar Doraghi talk contribs

			23:04		(Upload log)‎ [Kosar Doraghi‎ (2×)]
					23:04 Kosar Doraghi talk contribs uploaded File:IMG 1177.jpeg ‎
					22:59 Kosar Doraghi talk contribs uploaded File:IMG 1176.jpeg ‎

			m 23:02		Non-degenerate nucleotides per response element‎‎ 4 changes history +4,215‎ [Marshallsumter‎ (4×)]
			m		23:02 (cur \| prev) +2,787‎ Marshallsumter talk contribs (→‎Tabulation of counts)
			m		19:16 (cur \| prev) +570‎ Marshallsumter talk contribs (→‎Tabulation of counts)
			m		06:39 (cur \| prev) +506‎ Marshallsumter talk contribs (→‎Tabulation of counts)
			m		04:26 (cur \| prev) +352‎ Marshallsumter talk contribs (→‎Tabulation of counts)

			N 21:26		Tranexamic‎‎ 7 changes history +23,022‎ [Alara E. Dagsali‎ (7×)]
					21:26 (cur \| prev) +14‎ Alara E. Dagsali talk contribs Tag: Manual revert
					21:26 (cur \| prev) −11‎ Alara E. Dagsali talk contribs
					21:25 (cur \| prev) −2‎ Alara E. Dagsali talk contribs Tag: Manual revert
					21:23 (cur \| prev) −1‎ Alara E. Dagsali talk contribs
					21:23 (cur \| prev) +3‎ Alara E. Dagsali talk contribs Tag: Visual edit: Switched
					21:22 (cur \| prev) −1‎ Alara E. Dagsali talk contribs
			N		21:14 (cur \| prev) +23,020‎ Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage \|authorTag=Alara E.Dagsali \|genericName=Tranexamic \|aOrAn=a \|drugClass=hemophilia drug \|indicationType=prevention \|indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. \|adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines...")

			N 21:25		Template:AlaraE.Dagsali‎‎ 2 changes history +74‎ [Alara E. Dagsali‎ (2×)]
					21:25 (cur \| prev) −14‎ Alara E. Dagsali talk contribs
			N		21:21 (cur \| prev) +88‎ Alara E. Dagsali talk contribs (Created page with " Alara Ece Dagsali, M.D.[mailto:alaraecedagsali99@gmail.com]")

18:12

Hospital readmissions‎ diffhist +640‎ Badgettrg talk contribs (→‎Adults)

			07:55		SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY‎‎ 2 changes history +2,023‎ [Hafiza Amna Qadeer‎ (2×)]
					07:55 (cur \| prev) +965‎ Hafiza Amna Qadeer talk contribs
					07:52 (cur \| prev) +1,058‎ Hafiza Amna Qadeer talk contribs (added clinical features) Tag: Visual edit

23 April 2024

m 20:09

Non-degenerate nucleotides per response element‎ diffhist +108‎ Marshallsumter talk contribs (→‎Tabulation of counts)

Namespace:	Invert selection Associated namespace
Tag filter:	Invert selection

			18:58		User:AED‎‎ 4 changes history +85‎ [Alara E. Dagsali‎ (4×)]
					18:58 (cur \| prev) +20‎ Alara E. Dagsali talk contribs
					18:47 (cur \| prev) +22‎ Alara E. Dagsali talk contribs
					18:28 (cur \| prev) +20‎ Alara E. Dagsali talk contribs
					18:15 (cur \| prev) +23‎ Alara E. Dagsali talk contribs

			N 22:52		User:AED‎‎ 3 changes history +3,204‎ [Alara E. Dagsali‎ (3×)]
					22:52 (cur \| prev) −144‎ Alara E. Dagsali talk contribs
					22:51 (cur \| prev) +407‎ Alara E. Dagsali talk contribs
			N		22:39 (cur \| prev) +2,941‎ Alara E. Dagsali talk contribs (Created page with "==Alara Ece Dagsali== '''Alara Ece Dagsali''' <br>'''Contact:''' email: alaraecedagsai99@gmail.com; +905313614710 ==Medical Education== School of Medicine (M.D.): Istanbul Medipol University 2021- 2024 Demiroglu Bilim University 2018-2021 ==Pages authored/Co-authored/Collaborated== ===2023=== ====Authored:==== Reni Syndrome ==Work Experience== Wikidoc - Associate Editor-In-Chief, 2023 - Current Yeditepe University Hospitals Cardiac Electrophysiology Lab, Ista...")

			22:45		Tranexamic‎‎ 6 changes history +1‎ [Alara E. Dagsali‎ (6×)]
					22:45 (cur \| prev) +11‎ Alara E. Dagsali talk contribs
					22:44 (cur \| prev) −11‎ Alara E. Dagsali talk contribs
					22:41 (cur \| prev) +2‎ Alara E. Dagsali talk contribs
					22:41 (cur \| prev) −1‎ Alara E. Dagsali talk contribs
					22:40 (cur \| prev) +14‎ Alara E. Dagsali talk contribs Tag: Manual revert
					22:39 (cur \| prev) −14‎ Alara E. Dagsali talk contribs Tag: Manual revert

			N 21:21		Daprodustat‎‎ 6 changes history +6,894‎ [Alen Antony‎ (6×)]
					21:21 (cur \| prev) +952‎ Alen Antony talk contribs
					20:53 (cur \| prev) +1,266‎ Alen Antony talk contribs
					19:07 (cur \| prev) +2,809‎ Alen Antony talk contribs
					17:23 (cur \| prev) +563‎ Alen Antony talk contribs
					16:47 (cur \| prev) +147‎ Alen Antony talk contribs
			N		15:23 (cur \| prev) +1,157‎ Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage \|authorTag={{AAP}} \|genericName=daprodustat \|aOrAn=a \|drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. \|indicationType=treatment \|indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. \|hasBlackBoxWarning=Yes \|adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...")